The RSPCA has made a formal complaint against the Daily Telegraph to the Press Complaints Commission after the newspaper failed to print an apology or offer a right to reply after printing a series of articles which the charity considers potentially defamatory.
The RSPCA claims the stories are factually incorrect and 'reflect biased and unbalanced reporting style'.
The charity has taken particular issue with stories which, they say, claim it broke charity rules over the successful prosecution of a hunt and saying that the RSPCA was warned on hunt prosecutions by the Charity Commission. According to the RSPCA, the Charity Commission has been clear that no rules have been broken and no warning has been issued.
RSPCA chief executive Gavin Grant said: "These stories are a sustained attack on the RSPCA. The facts are that we have always and will continue to only act in the interests of the animals. We simply want the truth to be heard. The Daily Telegraph is entitled to its editorial position in support of blood sports despite the overwhelming public rejection of that view.
"They are not entitled to produce factually inaccurate articles that smear the good name of the RSPCA"
Liverpool based online CPD provider, The Webinar Vet reports that more than 350 veterinary surgeons from over 30 countries registered for its first virtual Veterinary Congress held earlier this month.
The one day congress consisted of six streams with top speakers from the UK, Australia and the USA covering radiology of the chest, cardiology, endocrinology, feline internal medicine, practice management and dermatology, totalling 18 hours of CPD.All six streams can still be accessed by delegates after the congress.
Anthony Chadwick MRCVS, founder of The Webinar Vet said: "Delegates were able to watch two streams on the day and then the other lectures at their leisure. And those who were unable to attend on the day, they can still register to access the congress.
"I was so pleased with the way the congress went. We had internationally renowned speakers being beamed into our homes without us having to go out in the cold wet weather to drive somewhere. Many of the early bird delegates also enjoyed the Fairtrade goodies we sent them in the post to enjoy during the coffee breaks."
Joe Hollins MA VetMB MRCVS, senior veterinary officer on the Island of St Helena has been based there since 2009, and believes that the Webinar Vet CPD has been a lifeline. He sent this message to the team: "Many congratulations to you and your team for putting together what must be deemed an historic event, the first ever virtual international veterinary congress. It's no mean feat. Your masterly control of proceedings, your cool, calm response to small technical glitches, the background coordination of proceedings by your staff; all this combined to create a useful, instructive, purposeful day.
"The fact that you manage to attract world class speakers says it all. My isolation in St Helena from 2009 initially presented me with major concerns regarding my CPD commitment, but The Webinar Vet has resolved any issues - and some. In fact my access to CPD has been greatly enhanced, and whether I was in the UK or not, I would encourage anyone involved in the profession to enrol."
Veterinary surgeons can buy recordings of the event at www.theinternationalwebinarvet.com
The Royal College has announced that a Legislative Reform Order (LRO) to reconstitute its disciplinary committees separately from its Council has been signed by Defra Minister David Heath, and will come into force on 6 April 2013.
The LRO will amend Part I of Schedule 2 of the Veterinary Surgeons Act 1966 (VSA) and require that the RCVS Preliminary Investigation and Disciplinary Committees are made up of veterinary surgeons and lay members who are not RCVS Council members, and who are appointed independently.
This will ensure that the same group of people is not responsible for setting the rules, investigating complaints and adjudication, and will bring lay people formally into the Preliminary Investigation Committee.
The LRO will also allow the RCVS to increase the pool of people available to investigate complaints and sit on disciplinary hearings, reducing the workload on the individual Committee members whose primary appointment is to RCVS Council.
The RCVS has been working on the LRO with Department of Environment, Food and Rural Affairs (Defra) officials since late 2010, and the Order was based on consultations undertaken by the RCVS and Defra.
According to the College, the Order was commended at every stage of Parliamentary scrutiny as an effective means to address the single biggest deficit of the VSA and to improve how the RCVS regulates the profession. During debate in Grand Committee of the House of Lords on 10 January, the RCVS received considerable praise for its strenuous efforts to modernise under the constraints of the present legislation, and the LRO received unanimous support.
Following the Order coming into force, the first external members will join the Disciplinary and Preliminary Investigation Committees from July 2013. After a two-year transition period, members of the RCVS Council will become ineligible for membership of these committees. Information about how to apply to join these committees will be available shortly.
President Jacqui Molyneux said: "I am delighted the LRO has been made and I am immensely thankful for the hard work of the Defra team and my colleagues in the College. The LRO is the single biggest reform to the regulation of veterinary surgeons since the 1966 Act, and it will bring the RCVS in line with regulatory best practice and improve the perception of the independence of the RCVS disciplinary processes."
Grahame Gardner is offering a 25% discount across many of its scrubwear ranges till the end of February 2013, including the Urbane Scrubs collection, the unisex Easiephit range and the Scrubzone brand.
For further information, visit www.grahamegardner.co.uk or call 0116 255 6326.
The University of Surrey has appointed Devereux Architects to create a masterplan for its new School of Veterinary Medicine.
As one of the University's largest and most prestigious future development sites, the new school, which sits within the Faculty of Health and Medical Sciences, will comprise three complimentary and inter-related buildings totalling approximately 9000m2 - an Academic Building, a Veterinary Clinical Skills Centre and a Veterinary Pathology Facility.
The new building will be positioned at the corner of the new campus green at Manor Park. It will feature naturally ventilated office and teaching spaces along one side of the atrium and research spaces and lecture halls along the other. The roof of the atrium is shaped to guide rising, warmed air into the plant room where the heat can be extracted and reused.
The new academic building will provide world-class teaching and research laboratories, lecture theatres, and flexible break out spaces organised around a common shared atrium.
Professor Lisa Roberts, Dean of the Faculty of Health and Medical Sciences, said: "We were very impressed with the design concept for the new School of Veterinary Medicine that Devereux Architects presented at the tendering stage. We are looking forward to working with the professional team at Devereux Architects to deliver this major project for the University of Surrey."
Elanco Animal Health is reminding vets about the importance of correctly interpreting oocyst counts in the diagnosis of coccidiosis during the post lambing period.
The company says scouring lambs that are failing to thrive should immediately ring the alarm bells for coccidiosis. Typically, oocyst counts of >20,000 per gram are cited as diagnostic for coccidiosis in sheep, but counts of up to 100,000 oocysts per gram have been reported in apparently healthy lambs and disease can also occur in the presence of low or negligible counts where there is gut damage but before oocysts have been shed.1 These discrepancies can lead to misdiagnosis and as such, oocyst counts should always be interpreted with care.
Oocysts of the fourteen Eimeria species described as specific to sheep are indistinguishable from each other by eye and only two species - E. ovinoidalis and E. crandallis, are actually pathogenic.1 For this reason, diagnosing coccidiosis based on clinical signs of diarrhoea and oocysts in their faeces alone can generate false positives. This could lead to important differentials, such as Nematodirus battus infection (for lambs at pasture) being left untreated.
According to the company, false negatives are also a concern, particularly as prompt treatment of clinical cases with an anti-coccidial, such as diclazuril (Vexocan® 2.5mg/ml oral suspension) has been proven to reduce the convalescence period.2 Shedding of oocysts varies with disease progression and faecal counts can fluctuate significantly.3 For example, a delay between the development of clinical signs and oocysts appearing in faeces is common. Another possibility is sub-clinical disease, with affected lambs showing no typical outward signs. The gut damage caused by the parasite can be significant in these animals though, adversely affecting growth rates.
Elanco says that for reliable diagnosis of coccidiosis, faecal oocyst counts should be considered alongside disease and farm history, followed with Eimeria species identification if possible. The disease typically affects groups of lambs aged between 3-8 weeks old and is often triggered by a stressor such as castration, weaning, turnout and/or bad weather. If clinical signs appear around three weeks after such an event, the suspicion of coccidiosis can be heightened. For some farms, predictable stressors cause disease outbreaks year after year and in these cases, a metaphylactic dose of Vecoxan® can be administered to susceptible lambs 14 days after the trigger event.
Finally, the company says veterinary surgeons should also not forget the importance of good management when advising farmers about coccidiosis control. Lambing pen and high traffic area hygiene and age batching lambs are essential for long term control.
References
Virbac has announced that it is hosting another day of CPD and surfing on Friday 26th April.
During the morning's session, Senior Field Veterinary Advisor Alex Allen BVM&S MRCVS will discuss 'Current thinking on companion animal vaccines', including CaniLeish, Virbac's vaccine for Leishmaniosis. Dermatologist Peri Lau-Gillard DrMedVet CertVD DipECVD MRCVS will then talk on 'Awful Atopics.'
The venue is the Atlantic Hotel, Newquay (close to Fistral Beach), with delegates transported to the nearby Surf School after lunch for their surfing lesson. A buffet lunch and post-surfing drinks will be provided by Virbac.
Territory manager and organiser Della Tomlinson said: "After last year's event we have had requests to repeat it from as far afield as London and Edinburgh, and we think that £30 for 3 hours of quality CPD is great value. As well as the obvious fun element of the surfing, we're deliberately holding the event on a Friday so vets can take advantage and enjoy a well-earned weekend away at a great location. Sadly this will have to be at your own expense!"
For more information or to book a place please contact Claire Lewis on 01359 243228 or claire.lewis@virbac.co.uk.
Welsh Environment Minister, John Griffiths, has announced changes to some bovine TB cattle and surveillance controls to provide a higher level of protection against the disease.
The Minister confirmed that from 1 April 2013, some existing Pre Movement Testing exemptions will be amended. The main changes concern movements from markets and common land.
New key measures are:
The Minister announced that a new dedicated TB epidemiologist was to be appointed for Wales and that he or she would work within the AHVLA and focus on specific areas or clusters of disease. The postholder will be in place by April 2013.
He also announced new advice and support to farms dealing with breakdowns: "I have also asked officials to develop a way to provide additional advice and support to farmers to clear up breakdowns more quickly and efficiently. We have started to explore how private vets could become more involved with this new initiative called the Integrated Breakdown Management Project.
"I know that bovine TB is a devastating disease that has a big impact in rural communities. Since I launched the Strategic Framework for Bovine TB Eradication last March, we have kept the programme under constant review. With the new tools I have outlined today, we are addressing TB in livestock and wildlife and maintaining an effective eradication programme for the benefit of farmers, rural communities and the economy in general."
Applications are now open for new members to join the RCVS Preliminary Investigation and Disciplinary Committees.
This is the first time that non-Council members have been able to sit on these two key committees, and follows the approval of a Legislative Reform Order (LRO) to the Veterinary Surgeons Act, which comes into force on 6 April 2013.
Under the new legislation, the two statutory committees will move through a transition period until they completely comprise independently-appointed non-Council members, by July 2015.
This move will provide regulation in line with modern practice, by ensuring that the same group of people is not responsible for setting the rules, investigating complaints and adjudication, and by bringing lay people formally into the Preliminary Investigation Committee.
This first recruitment phase seeks:
RCVS President, Jacqui Molyneux said: "It's exciting that we can now seek to appoint non-Council members to the two committees involved in our disciplinary system - a breakthrough that has taken a long time to achieve.
"We are interested to hear from veterinary surgeons and lay people who are keen to contribute to the public good and support us in our regulatory role. It's an excellent opportunity to be part of the next chapter of the RCVS, as we become a more modern and effective regulator."
The recruitment process is being handled by Thewlis Graham Associates and details can be found at www.thewlisgraham.com. The selection committee will comprise Sir Michael Buckley, Christopher Laurence MBE QVRM TD BVSc MRCVS and Dr Joan Martin MA FCOT.
The closing deadline for applications is 5pm on Monday 4 March 2013.
Eclipse Veterinary Software has released a new mobile addition to its equine veterinary practice management system.
Eclipse Mobile allows veterinary surgeons to access up-to-date clinical information wherever it is needed, be that on the yard, at the practice, or while making field visits.
When Eclipse Mobile is offline, all the information the vet needs is stored on the device. When next connected via 3G or Wi-Fi, any new details are sent to and from the practice - syncing notes made by the vet, adding follow-on appointments and To Do messages, services delivered and products administered to keep everyone up-to-date throughout the day.
Whilst online, client payments can be taken via debit/ credit cards within the app and detailed drug batch information recorded using the iPad/iPhone's camera as a barcode scanner, if required.
Jeanne Razzell, CEO of Eclipse said: "Many of the vets we work with have been keen to carry animal histories with them on visits, including the latest lab test results, together with recent clinical notes, and diagnostic imaging, e.g. x-rays, ultrasounds and MRI, CT or bone scans. Now, with Eclipse Mobile, every vet can have all of this information at their fingertips automatically - at every appointment; both in the consult room and on the road."
Eclipse Mobile is available for iPad, iPad mini, iPhone, Android smart phones/tablets and Microsoft Windows Surface
For more information, contact Jeanne Razzell, CEO, Eclipse Veterinary Software Limited, on +44 (0)1799 532988 or +44 (0)7515 906466. Website: www.eclipsesoftware.info
The British Veterinary Association (BVA) is calling on the Veterinary Medicines Directorate to classify all anthelmintics as POM-V, so that they can only be prescribed by a veterinary surgeon, rather than by vets and Suitably Qualified Person (SQPs) as at present.
The BVA has written to the VMD to request that changes are made to the Veterinary Medicines Regulations. The BVA is also supporting the efforts of the Federation of Veterinarians of Europe in lobbying the European Commission for tighter rules to be in place across all European Member States regarding the accessibility of anthelmintics.
The BVA says that at a time when expert opinion is increasingly alarmed at the growth in resistance to anthelmintics in grazing animals, it believes that it is important that all anthelmintics be classified as POM-V so that their use is conditional on appropriate veterinary advice for all species.
Many experts in parasitology have cited the distribution of anthelmintics by SQPs in the past as one of the main reasons for the dangerous levels of resistance to anthelmintics in grazing animals in the UK at present. SQPs do not have the level of expertise that a veterinary surgeon has in veterinary parasitology.
BVA is an active member of the Responsible Use of Medicines in Agriculture (RUMA) Alliance and in 2010 BVA launched a poster and detailed guidance for vets on how to prescribe and use anthelmintics responsibly. BVA's CPD Group is also working on a programme of CPD to reinforce the responsible use of these medicines.
Peter Jones, BVA President said: "We know that resistance to anthelmintics is a major problem that must be addressed vigorously if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites in grazing animals.
"Anthelmintics should only be prescribed by a veterinary surgeon who has the animals under his/her care and based on a sound clinical diagnosis.
"We strongly supported the VMD's recent decision to continue to classify the new anthelmintic product containing monepantel as POM-V, but the UK stands alone in Europe in classifying other anthelmintics as POM-VPS.
"The UK must be brought in line with the rest of Europe and we need Europe-wide legislation to better control access to anthelmintics in order to safeguard the efficacy of these products in the future."
According to the company, the new injectable form of Vetmedin provides rapid acting treatment for canine congestive heart failure originating from valvular insufficiency (e.g. mitral valve disease, MVD) or dilated cardiomyopathy (DCM). Twelve hours after the injection is administered, treatment can be continued by the dog's owner with Vetmedin flavour tablets or Vetmedin hard capsules at the recommended dosage.
Ruth Willis BVM&S DVC MRCVS, RCVS Recognised Specialist in Cardiology said: "Parenteral administration of medicines is often preferred in cases of acute congestive heart failure to help minimise patient stress and clinical deterioration. Vetmedin Solution for Injection is therefore a useful addition to our armoury of products for the treatment of acute congestive heart failure due to MVD or DCM."
The injection contains 0.75 mg/ml of the active ingredient, pimobendan, and it is supplied in 5 ml single use vials at the licensed dose of 0.15 mg/kg, with one vial treating a dog up to 25 kg.
In association with the Vets Now emergency treatment service, Boehringer has produced an algorithm which features step-by-step guidance on the recommended treatment protocol for dogs with acute congestive heart failure due to MVD or DCM, together with point of sale material including shelf wobblers for use in practice to raise awareness of the product.
The company is also hosting a free cardiology webinar presented by Ruth Willis entitled 'Acute CHF - a stress free approach'. The online seminar takes place at 8.00pm on Tuesday 19 February and counts for one hour's CPD. The webinar will be available to view after the live event on demand. To register, visit http://www.bi-academy.co.uk/.
For further information, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
The Animal Medicines Distributors Association (AHDA) and the Animal Medicines Training Regulatory Authority (AMTRA) have both come out against the BVA's call for all anthelmintic medicines to be reclassified as POM-V, which would prevent them being prescribed by Suitably Qualified Persons (SQP).
Ian Scott, Secretary General of AHDA, said that instead of launching an attack on SQPs, the BVA should be working with them and animal owners to tackle anthelmintic resistance: "The BVA has written to the VMD to ask that all anthemintics be classified to POM-V only. This will monopolise the supply and distribution of anthelmintics for vets only. It effectively places the blame for anthelmintic resistance squarely on SQPs.
"An attempt by BVA to create a division between vets and SQPs demonstrates that the BVA is out of touch with its members.
"Both prescribing channels must work together to tackle the problem and AHDA has been working hard with vets at national and local level to ensure customers receive consistent, high quality, up-to-date and relevant advice from both channels.
"What is worrying is that the BVA attack also infers that farmer producers and equine owners are incapable of making decisions that not only affect their livelihood but cast doubt on their ability to care for their animals' welfare."
Meanwhile, Stephen Dawson, Secretary General of AMTRA said: "The large majority of SQPs deal with parasite control on a daily basis, having trained and been examined to a syllabus developed with BVA input. SQPs have to undertake compulsory continuing professional development, the majority of which includes good practice in parasite control. Therefore AMTRA has every confidence that qualified SQPs have excellent knowledge of parasitology to advise their clients on the correct choice and use of anthelmintics.
"It is important to recognise the hard work, knowledge and dedication of thousands of SQPs throughout the UK. The implication of what BVA say is that they are laying a proportion of the blame for resistance to these medicines at the door of SQPs. But the evidence isn't there: countries in Europe and elsewhere with different prescription systems, mainly though vet-only channels, still have major resistance problems. Prescription of antimicrobials by veterinary surgeons hasn't prevented concerns about prescribing practices and developing resistance. The key point is good advice from the prescriber and how they are then used in practice, rather than who prescribes them. The challenge for us all is not just to seek excellence in prescribing but also in usage on farm, something SQPs are ideally placed to do with their frequent farmer contact.
"I would urge all parties to work in partnership to ensure that best practice in prescription and use is followed by all prescribers and users. It is up to all prescribers to act responsibly, but to single out one group over another is unjustified. A pseudo-monopoly by vets on supply would do nothing to help farmers in difficult times."
Mr Dawson also expressed doubts about permanent POM-V status for new livestock anthelmintics: "While we fully support VMD's and VPC's need to be sure that the risk associated with wider availability of a new product is low, AMTRA considers that the current division in distribution classes and consequent low uptake of the newer products means that the much bigger risk is that widespread reliance on the three aging classes may be followed by reliance on just the two new classes when the older classes become unusable. Much better to have responsible prescription of all five classes now, by appropriately trained SQPs, vets and pharmacists, to ensure that there is a prospect of long term availability of effective parasite control."
The Department for Environment, Food and Rural Affairs (Defra) and the Food Standards Agency (FSA) are reminding veterinary surgeons of their legal responsibilities under the Horse Passport Regulations 2009.
The move follows a small number of horses testing positively for the presence of phenylbutazone, which, if consumed, can be harmful to human health.
Defra and the FSA have asked for the assistance of the profession in ensuring that treatment with phenylbutazone is properly recorded in Horse Passports and have said that they are working together to understand the cause of the positive tests, and what longer term measures can be put in place to stop this happening.
In the interim, all horses slaughtered for human consumption will be sampled for the presence of phenylbutazone, with immediate effect.
The letter from Defra and the FSA can be downloaded from the RCVS website.
The full advice can be read in a Veterinary Medicines Directorate/Defra leaflet, which can be found online at http://www.vmd.defra.gov.uk/pdf/leaflet_horses.pdf.
Mark Bowen, Chair of the British Equine Veterinary Association's Health and Medicines Committee, said: "The number of horses entering the human food chain from the UK has doubled since 2009 and is no longer an insignificant minority of horses. All vets should be checking horse passports and only dispensing sensible quantities of this drug, and its prodrug suxibuzone."
Meanwhile, a form is available from the British Equine Veterinary Association website for veterinary surgeons to use if the horse passport is not available, but emergency treatment is required: http://www.beva.org.uk/_uploads/documents/emergency-treatment-form-no-passport-2011.pdf
The British Small Animal Association has responded to Defra's statement on compulsory microchipping.
The Association says it is an advocate of compulsory microchipping as the most effective way to permanently identify a dog - as long as owners maintain an up-to-date registration on the various databases. As such it broadly welcomes the recent Defra statement.
However, BSAVA points out that the statement has come before a full and considered consultation in terms of its implementation, and says it raises a number of questions for vets in practice:
Despite the headlines around the statement, this is yet to be laid down in law and will require changes under the Animal Welfare Act and potentially the Dangerous Dogs Act, so there is still a conversation to be had about its implementation.
For this reason BSAVA has announced that it is launching a consultation with its members to establish their concerns and opinions in order to work with all the organisations involved in the best interest of animal welfare and the profession. If anyone in practice wants to feed into this consultation, they should visit http://www.bsava.com or contact BSAVA's Scientific Policy Officer Sally Everitt via email - s.everitt@bsava.com.
BSAVA President Mark Johnston said: "While implantation can be straightforward for those with appropriate experience it will be important to ensure that all those who carry out implantation are properly trained. However microchipping is not just a matter of implanting the microchip, there is a significant amount of administrative work in ensuring that animals are properly registered and that details are kept up-to-date. All of these stages need to be properly funded if the scheme is to be successful and sustainable. BSAVA will be consulting its members to gather their views and concerns and hope to be involved in a productive conversation with all interested parties."
BSAVA says there is a good news animal welfare story within this statement concerning the seizure of animals during investigation under the Dangerous Dogs Act. The new measures will allow the authorities to decide whether a suspected prohibited dog can stay with their owners until the outcome of court proceedings. Until now all such animals had to be kennelled until the proceedings had concluded, which often means that dogs who posed no risk suffered unnecessarily. BSAVA welcomes this new measure in the interest of animal welfare.
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
The British Equine Veterinary Association (BEVA) has launched two guides to help veterinary professionals and their clients negotiate the complexities of equine insurance.
BEVA highlights that with up to 40% of horses becoming ill or injured in any one year and 25% of insured horses having a claim in any one year, vet fees insurance is a sensible way for horse owners to budget for unexpected healthcare costs.
The Veterinary Surgeon's guide to riding and sport horse insurance provides general guidelines to help vets understand the requirements and issues relating to equine insurance. It explains the three main types of insurance cover available: veterinary fees, death and permanent loss of use, as well as insurance recommendations for pre-purchase and pre-insurance vetting. The final section contains a jargon-busting guide to commonly used insurance terminology.
Complementing the vet guide is The BEVA leisure and sports horse Insurance Guide for horse owners, a handout for clients about to embark on taking out insurance. It covers the frequently asked questions relating to vets fees and death, including when and how to insure, the importance of pre-purchase vetting, exclusions and permanent loss of use.
Andrew Harrison, Junior Vice President of BEVA, said: "Whether a vet or a horse owner, understanding equine insurance can be intimidating for the best of us. The new guides should make it easier for you and your clients to understand the finer points of policies, premiums and claim protocols."
The guides can be downloaded from the BEVA website via the following links:
For additional information visit www.beva.org.uk
Life Technologies Animal Health has announced the launch of a new qPCR test to improve the diagnosis of mastitis and respiratory disease caused by Mycoplasma bovis.
According to the company, the TaqVet Mycoplasma Bovis (M. bovis) polymerase chain reaction (PCR) kit is based on a new target gene in the M. bovis genome and thus can distinguish better between infections caused by M. bovis and M. agalactiae - so there is less risk of false positive results and improved sensitivity and specificity.
The test is based on real-time PCR technology, and delivers results in two and a half hours.
Eric Sellal, Head of Animal Health EMEA at Life Technologies said: "The improved sensitivity of this new test means that veterinarians will be able to monitor dairy herds for sub-clinical infection using samples from the bulk tank. And of course it can also be used to diagnose mycoplasma infection in individual cases of clinical mastitis and respiratory disease."
Life Technologies says the test system incorporates a number of other improvements which simplify and speed up processing in the laboratory, including automatic extraction using magnetic bead technology.
It is estimated that bovine pneumonia costs the European industry around 500million Euros each year, with 30% accounted for by M. bovis. Other diseases associated with the organism include mastitis and arthritis.
Mycoplasma is slow and difficult to culture in the laboratory and current antibiotic treatment is not very cost-effective. Therefore, prevention is a cornerstone of M. bovis management.
The TaqVet Mycoplasma Bovis PCR kit will be made available in other EU countries and via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
BCF Technology has launched the Sonosite Edge ultrasound system.
According to the company, the new system is suitable for both small animal and equine reproduction, abdominal, musculoskeletal, cardiac and ophthalmic applications.
The Sonosite Edge was apparently designed for use in battlefields and disaster zones, so it should withstand veterinary use. It is upgradeable to Colour, Pulsed Wave (PW) and Continuous Wave (CW) Doppler. It can also be DICOM enabled. It weighs 15kg and has a start up time of less than 15 seconds. There is a range of linear, mico-convex, convex and phased array probes available.
The system with one probe starts around £22,000.
Nigel Perry, BCF Account Manager said: "The Sonosite Edge offers an excellent system with superior image quality than has not been seen on a field-based system before. This is a perfect system for a mixed practice looking to perform a wide range of applications. It is very durable and can be taken anywhere."
To find out more about the Sonosite Edge, visit www.bcftechnology.co.uk or call +44(0)1506 460 023.
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
Invicta Animal Health has been appointed exclusive UK distributor of EquiChek, a rapid screening test which uses whole blood to assess the level of Serum Amyloid A (SAA), a major acute phase protein of inflammation in horses.
According to the company, EquiChek is the first test which is able to provide a visual semi-quantitative result within 15 minutes. The test will display 4 lines for a normal level of SAA and sequentially fewer lines depending on the severity of the inflammation.
Rob Watkins, Managing Director of Invicta, said: "Monitoring SAA levels in horses is a well-documented method of indicating a variety of conditions and for assessing health/inflammatory status prior to performance. However, the needs for equipment and time to perform the tests have always limited the situations in which it can be used.
"EquiChek changes all that. A stableside test for SAA means that monitoring real-time becomes a reality. Whether for tailoring antibiotic therapy, to check pre-breeding health status through to pre-competition health assessment, the applications are literally endless".
For further information see www.invictavet.com or phone 01403 791313
The Advertising Standards Authority has decided not to uphold complaints against the Morrisons Christmas TV advertisement.
The full adjudication can be read here.
Peter Jones, President of the British Veterinary Association, said: "This ruling is disappointing but the ASA has set out its reasons for the decision and we accept those reasons. Thankfully, the advert only had a short shelf life and we hope that Morrisons is now very unlikely to make the same mistakes again. Overall, we hope the whole incident has served to educate Morrisons and the general public about the dangers of grapes and raisins to dogs."
Defra Minister David Heath has announced the latest bute (phenylbutazone) test results. The presence of bute has been confirmed in 8 samples out of 206 tests.
Chief Medical Officer Professor Dame Sally Davies has stated that horsemeat containing phenylbutazone presents a very low risk to human health.
Responding to these latest developments the British Veterinary Association (BVA) and British Equine Veterinary Association (BEVA) have issued the following statement:
"The presence of phenylbutazone (or bute) in horses intended for the food chain will be of concern to consumers who rightly expect the UK food chain to be robust. We are grateful to the Chief Medical Officer for clarifying the very low level of risk that this presents to human health and we will work with the FSA and Defra in any way we can to assist their investigations into these incidents.
"The ability to treat horses with bute is very important for equine welfare. Bute provides affordable, long-term pain relief for horses and is unique in this respect.
"The UK Horse Passport Regulations are designed to facilitate the ongoing medical treatment of horses not intended for the human food chain, whilst ensuring that these animals do not enter the food chain.
"We fully support the concept of the Horse Passport Regulations but have argued for some time that there are problems with the system in terms of the number of Passport Issuing Authorities and the vulnerability of the system to fraud. We are very keen to continue our dialogue with Defra and others to find ways to make the system more robust.
"Our members are aware of the strict rules regarding the regulation of medicines (including bute) and the use of horse passports, and in recent years we have provided clear guidance on the regulations to help both vets and their clients. These incidents will hopefully reinforce these messages amongst horse owners and all of us involved in equine healthcare."
Guidance notes are available via the BEVA website Medicines Page (http://www.beva.org.uk/useful-info/Vets/Guidance/Medicines)
Researchers from the School of Veterinary Sciences at the University of Bristol have had a study into domestic dogs' fear responses to noise published in Applied Animal Behaviour Science.
According to the University, the study provides an important insight into dogs' fear of noises, and could improve our understanding of behavioural signs of fear or anxiety.
In the study two approaches were taken to investigate the occurrence of, and risk factors for, behaviours caused by a fear of noise: a postal survey of dog owners to investigate general demographic factors and a structured interview of a sub-set of owners to gather more detailed information.
It seems that while owners are often aware of their pet's behavioural response when exposed to a loud noise, they do not necessarily recognise it as being indicative of fear or anxiety. This has relevance both for awareness of compromised welfare, and the methodology for surveying such behaviour.
According to the researchers, other behavioural signs, such as decreased activity or salivation, may not be as easily recognised by owners as signs of fear, and may be under-reported. Also, signs of urination, salivation and destruction may make owners disappointed or angry, and this may influence their interpretation that such behaviours are associated with fearfulness.
The risk factors for owner-reported fear of noises included:
The researchers suggest a dog's early life experience is an important factor in the development of fear responses to specific loud noises.
Dr Rachel Casey, European Specialist in Veterinary Behavioural Medicine and Senior Lecturer in Companion Animal Behaviour and Welfare at Bristol University, said: "Our results suggest that the characteristics of dogs, their early environment, and exposure to specific loud noises are involved in the development of fear responses to noises. Interestingly, less than a third of owners sought professional advice about treatment for their pet's response to noises."
Disappointingly, less than a third of owners currently seek professional advice about treatment for their pet's fear. The researchers recommend there is a need for veterinary surgeons to increase awareness among the general dog owning public that treatment is both available and effective in dealing with fears of loud noises, and to direct them towards appropriate sources of help.
Information for vets and dog owners on finding an expert to help treat behaviour problems including fear of noises can be found at www.rspca.org.uk/findabehaviourist
Paper: Fear responses to noises in domestic dogs: Prevalence, risk factors and co-occurrence with other fear related behaviour, Emily J. Blackwell, John W.S. Bradshaw, Rachel A. Casey, Applied Animal Behaviour Science, published online 22 January 2013.
Davies Veterinary Specialists (DVS), the private small animal referral centre based in Hertfordshire, has installed two new state-of-the-art ESAOTE ultrasound machines.
DVS says The MyLab Twice Vet and the MyLab Class C Vet provide fast, efficient and highly accurate imaging in a wide range of applications, including high-definition abdominal, cardiac, musculoskeletal and ophthalmic scans.
The MyLab Twice Vet, with its range of probes including the broadband 18MHz linear probe, will be used for general ultrasonographic imaging at DVS. It is capable of the most refined contrast media examinations that, for example, can help to locate and identify a liver tumour that may be rendered invisible when using conventional diagnostic procedures.
The MyLab Class C will be used predominantly for advanced cardiac work, including trans-oesophageal echocardiography for interventional procedures in theatre.
Pedro Oliveira, European Veterinary Specialist in Cardiology at DVS said: "The trans-oesophageal probe is currently a very rare piece of equipment in veterinary diagnostics. It gives us the capacity to obtain unique views of the heart, especially the heart base which can be a very difficult area to examine with regular echocardiography. It also allows real-time and direct monitoring of procedures, such as deployment of devices to occlude patent ductus arteriosus, surgery and anaesthesia in critical patients."
The first patient to benefit from the new My Lab Class C was an 11-year-old, female German shepherd dog with suspected cardiac neoplasia following several episodes of haemorrhage into the pericardium. A normal echocardiographic examination identified a small suspect area but it was in a part of the heart that was very difficult to approach surgically.
However, a trans-oesophageal examination revealed that another small mass close to the tip of the right auricle was actually the origin of the bleeding. The dog underwent surgery to remove the mass and subsequently made a full recovery. Without the My Lab Class C there would have been no viable options for this dog.
Clive Elwood, Managing Director at DVS, said: "Combining the best possible on-site diagnostic equipment with some of Europe's finest clinicians enables us to provide the best possible service and outcome for our patients, across multiple disciplines."